ExpreS2ion CEO: “Compelling preclinical package gives us confidence”
Based on its proprietary protein expression platform, ExpreS2ion Biotech advances its ES2B-C001 breast cancer vaccine candidate toward clinical studies.
A SEK 60 million rights issue is underway to fund this pivotal step. CEO Bent U.
Frandsen discussed the current development and the future plans ahead with BioStock.